{"id":"W4388092012","doi":"10.1016/j.jtho.2023.09.232","title":"MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Stage (stratigraphy); Internal medicine; Retrospective cohort study; Observational study; Overall survival; Population; Oncology; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009357611,0.0007080451,0.0007942735,0.0004823026,0.001288919,0.001705935,0.00156567,0.0008079881,0.002837431],"category_scores_gemma":[0.003591691,0.0003535599,0.001764099,0.001890655,0.0007396576,0.0005930767,0.0008708021,0.001506403,0.0003798434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.03571763,"about_ca_system_score_gemma":0.03615293,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9759467,"about_ca_topic_score_gemma":0.9847082,"domain_scores_codex":[0.9988726,0.0001522756,0.00005843298,0.0002130279,0.0002880062,0.0004156455],"domain_scores_gemma":[0.9971246,0.0002705241,0.0006408239,0.0001517666,0.0009703495,0.000842008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008000451,0.0002632097,0.962006,0.0003487693,0.002020926,0.0002462988,0.0003990355,0.001575255,0.0003850202,0.0004179022,0.009099815,0.01523714],"study_design_scores_gemma":[0.0006839446,0.0004491818,0.9907782,0.0001327261,0.00128382,0.0001556385,0.000659878,0.001224956,0.000120285,0.0001224832,0.004330978,0.000057869],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9670436,0.003031983,0.0001551301,0.001469568,0.00008150726,0.0001170422,0.0246556,0.00002566748,0.00341986],"genre_scores_gemma":[0.9887329,0.0009853211,0.000207774,0.0003797541,0.00006276945,0.00004579689,0.008078167,0.00001783002,0.00148965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03571763,"threshold_uncertainty_score":0.2591507,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03726675609655791,"score_gpt":0.4474466065650997,"score_spread":0.4101798504685418,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}